LEXEO THERAPEUTICS INC (LXEO)
US52886X1072 - Common Stock
ChartMill assigns a Buy % Consensus number of 86% to LXEO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 22.88. This target is 199.44% above the current price.
LXEO was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about LXEO.
In the previous month the buy percentage consensus was at a similar level.
LXEO was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-13 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-30 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-13 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-06-13 | Baird | Initiate | Outperform |
| 2024-06-06 | HC Wainwright & Co. | Initiate | Buy |
| 2024-03-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-11-28 | Leerink Partners | Initiate | Outperform |
| 2023-11-28 | Chardan Capital | Initiate | Buy |
| 2023-11-28 | RBC Capital | Initiate | Outperform |
| 2023-11-28 | Stifel | Initiate | Buy |
| 2023-11-28 | JP Morgan | Initiate | Overweight |